Tubular Endogenous Erythropoietin Protects Renal Function against Ischemic Reperfusion Injury
Authors:
- Yukiko YasuokaYYYukiko Yasuoka
- Yuichiro IzumiYIYuichiro Izumi
- Takashi FukuyamaTFTakashi Fukuyama
- Tomomi OshimaTOTomomi Oshima
- Taiga YamazakiTYTaiga Yamazaki
- Takayuki UematsuTUTakayuki Uematsu
- Noritada KobayashiNKNoritada Kobayashi
- Masayoshi NanamiMNMasayoshi Nanami
- Yoshitaka ShimadaYSYoshitaka Shimada
- Yasushi NagabaYNYasushi Nagaba
- Masashi MukoyamaMMMasashi Mukoyama
- Jeff M. SandsJSJeff M. Sands
Open Access
- 19 January 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (2) , 1223
Abstract
Many large-scale studies show that exogenous erythropoietin, erythropoiesis-stimulating agents, lack any renoprotective effects. We investigated the effects of endogenous erythropoietin on renal function in kidney ischemic reperfusion injury (IRI) using the prolyl hydroxylase domain (PHD) inhibitor, Roxadustat (ROX). Four h of hypoxia (7% O2) and 4 h treatment by ROX prior to IRI did not improve renal function. In contrast, 24–72 h pretreatment by ROX significantly improved the decline of renal function caused by IRI. Hypoxia and 4 h ROX increased interstitial cells-derived Epo production by 75- and 6-fold, respectively, before IRI, and worked similarly to exogenous Epo. ROX treatment for 24–72 h increased Epo production during IRI by 9-fold. Immunohistochemistry revealed that 24 h ROX treatment induced Epo production in proximal and distal tubules and worked similarly to endogenous Epo. Our data show that tubular endogenous Epo production induced by 24–72 h ROX treatment results in renoprotection but peritubular exogenous Epo production by interstitial cells induced by hypoxia and 4 h ROX treatment did not. Stimulation of tubular, but not peritubular, Epo production may link to renoprotection.Keywords
All Related Versions
Funding Information
- Ministry of Education, Culture, Sports, Sciences, and Technology of Japan (18K08247, 19K09226, H25-003, H24-011)
- Science Research Promotion Fund from the Promotion Department at the Kitasato University Medical Center (18K08247, 19K09226, H25-003, H24-011)
This publication has 55 references indexed in Scilit:
- Peginesatide for Anemia in Patients with Chronic Kidney Disease Not Receiving DialysisNew England Journal of Medicine, 2013
- Peginesatide in Patients with Anemia Undergoing HemodialysisNew England Journal of Medicine, 2013
- Preischemic targeting of HIF prolyl hydroxylation inhibits fibrosis associated with acute kidney injuryAmerican Journal of Physiology-Renal Physiology, 2012
- Regulation of erythropoietin productionThe Journal of Physiology, 2011
- Repression via the GATA box is essential for tissue-specific erythropoietin gene expressionBlood, 2008
- The non‐haematopoietic biological effects of erythropoietinBritish Journal of Haematology, 2008
- Preconditional Activation of Hypoxia-Inducible Factors Ameliorates Ischemic Acute Renal FailureJournal of the American Society of Nephrology, 2006
- Enhanced erythropoiesis mediated by activation of the renin‐angiotensin system via angiotensin II type 1a receptorThe FASEB Journal, 2005
- Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathwayKidney International, 2001
- Isolation and characterization of genomic and cDNA clones of human erythropoietinNature, 1985